Prostate Cancer - Results from #2140

Ten-year work burden after prostate cancer treatment. September 21, 2023

Tumor-derived biomarkers predict efficacy of B7H3 antibody-drug conjugate treatment in metastatic prostate cancer models. September 21, 2023

Prehabilitative versus rehabilitative exercise in prostate cancer patients undergoing prostatectomy. September 21, 2023

Biomarker-Directed Therapy in Black and White Men With Metastatic Castration-Resistant Prostate Cancer. September 20, 2023

In-Hospital Venous Thromboembolism and Pulmonary Embolism After Major Urologic Cancer Surgery. September 20, 2023

Baseline prostate health index risk category and risk category changes during active surveillance predict grade reclassification. September 20, 2023

Efficacy and safety of PARP inhibitors in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of clinical trials. September 20, 2023

Poly (ADP-ribose) Polymerase Inhibitors Have Comparable Efficacy with Platinum Chemotherapy in Patients with BRCA-positive Metastatic Castration-resistant Prostate Cancer. A Systematic Review and Meta-analysis. September 20, 2023

Evaluation of a Deep Learning-based Algorithm for Post-Radiotherapy Prostate Cancer Local Recurrence Detection Using Biparametric MRI. September 19, 2023

Prostate Cancer Screening in African American Men: A Review of the Evidence. September 19, 2023

Impact of Concomitant Cardiovascular Therapies on Efficacy and Safety of Relugolix vs Leuprolide: Subgroup Analysis from HERO Study in Advanced Prostate Cancer. September 19, 2023

Relative impact of lymph-node metastasis and seminal vesical invasion on oncologic outcomes following radical prostatectomy. September 19, 2023

Practical Guidance on Establishing a Molecular Testing Pathway for Alterations in Homologous Recombination Repair Genes in Clinical Practice for Patients with Metastatic Prostate Cancer. September 19, 2023

Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial. September 19, 2023

ESSA Pharma Announces Initiation of Phase 2 Study Evaluating Masofaniten (EPI-7386) in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer September 18, 2023

MRI-Based Radiomics Analysis of Levator Ani Muscle for Predicting Urine Incontinence after Robot-Assisted Radical Prostatectomy September 18, 2023

[177Lu]Lu-PSMA-617 Versus Docetaxel in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: Final Survival Analysis of a Phase 2 Randomized, Controlled Trial. September 18, 2023

Racial differences in patient-reported outcomes among men treated with radical prostatectomy for prostate cancer. September 18, 2023

Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer: A subgroup analysis of the randomised clinical TITAN study. September 18, 2023

Diagnostic concordance between traditional and digital workflows. A study on 1427 prostate biopsies. September 18, 2023

Page 108 of 1439